DividendMay 27, 2026

Dividend Win Wednesday: Energy Insiders Buy 1.4M Shares While the Market Sleeps

Top 5 Pixie Picks

This Week's Setup

The dividend screener rotates back to energy and pharma, parking ConocoPhillips and Newmont at Pixie Ranks 1 and 2 with FCF yields above 5% and drawdowns stretching to 18%. Greed at 61 keeps passive flows elevated, but S&P 500 CAPE at 38.9 flags that the market is priced for perfection while these names sit 10–18% below 52-week highs.

Insider activity clusters around energy: ConocoPhillips logged three Form 4 filings in the last 30 days, EOG Resources added 128,000 net shares, and Exxon insiders bought 1.05 million shares at a 4-to-1 buy-to-sell ratio.

Quick Scan

#	Ticker	One-line thesis
1	COP	5.1% FCF yield, 14% drawdown, triple insider adds
2	NEM	6.2% FCF yield, 18% drawdown, 30% analyst upside
3	NVS	3.2% yield, 76% gross margin, kidney data
4	EOG	7.4% earnings yield, 128K insider shares added
5	BIIB	6.9% FCF yield, 84K insider adds, MS probe
6	GILD	Phase 3 liver win, 274K insider shares
7	GSK	3.5% yield, 74% earnings yield, Arexvy expansion
8	XOM	1.05M insider shares, Venezuela talks, 15% drawdown

The 8 Names

1. ConocoPhillips (COP)

Dividend yield: 2.9% | Payout ratio: 51% | 52w drawdown: 14%

FCF yield sits at 5.1% while the stock trades 14% below its 52-week peak, creating a setup where the company generates $5.10 in free cash for every $100 of market cap. Earnings yield of 5.1% clears the bond alternative by 450 basis points, and ROIC of 13.5% signals the company reinvests capital at rates that justify the equity risk premium.

Three insiders filed Form 4 purchases in the last 30 days: Andres Felipe Mejia Cardona, Ricardo Jaramillo Mejia, and Sylvia Escovar Gomez all added shares on May 21. Net insider purchases total 256,539 shares over six months, a 1.2% increase in insider holdings against a 1.0% decrease from sales.

Revenue growth of 7.7% year-over-year looks strong until you note it trails the 10.8% average for the energy sector, and the stock's 1-year price trend of 0.16% reveals a name stuck in neutral while crude oscillates. Mizuho lifted the price target to $150 from $136, embedding 29% upside from here, but that optimism hinges on Venezuela safeguards materializing and Exxon-ConocoPhillips coordination on return timelines.

2. Newmont Corporation (NEM)

Dividend yield: 0.9% | Payout ratio: 16% | 52w drawdown: 18%

The 6.2% FCF yield at an 18% drawdown creates the highest cash-generation-to-price dislocation on this week's screen, and the 29.4% analyst target spread to $143.48 implies the market is underpricing both the gold position and the operational leverage. ROIC of 29.9% and gross margin of 53.2% put Newmont in the top quartile of the mining complex for capital efficiency, and the company carries net cash, not net debt.

Deborah Leyva, David John Thornton, and Maura J. Clark each filed Form 4 adds in May, pushing net insider shares up 16,605 over six months. The 2.7% insider buy ratio against 2.1% sell ratio is modest in absolute terms but notable when most miners see net selling at this stage of the gold cycle.

The dividend yield of 0.9% and 16% payout ratio flag that Newmont prioritizes balance-sheet flexibility over income distribution, making this a total-return play, not a yield play. The $110.92 price sits 18% below the 52-week high despite revenue growth of 21.3% year-over-year, signaling the market wants proof that the new asset base translates into sustained margin expansion before re-rating the equity.

3. Novartis AG (NVS)

Dividend yield: 3.2% | Payout ratio: 65% | 52w drawdown: 12%

FCF yield of 5.3% at a 65% payout ratio leaves 35% of free cash flow for debt reduction, buybacks, or M&A, and the 76% gross margin gives Novartis pricing power that buffers against input-cost inflation. Earnings yield of 4.6% clears the 10-year Treasury by 460 basis points, and ROIC of 16.0% validates the patent-protected portfolio thesis.

New kidney-disease data at the ERA 2026 conference this week reinforces the renal franchise, which contributes $3.2 billion in annual revenue and competes directly against AstraZeneca's Farxiga and Bayer's Kerendia. The global IVP Assay Repository launch with Zifo and the Pistoia Alliance positions Novartis as a data-infrastructure player in the precision-medicine buildout, which matters for long-cycle competitive advantage.

The 2.1% analyst upside to $153.87 is the narrowest spread on the screen, signaling that the Street sees the stock as fairly valued at 21.6× earnings. Net debt of 1.75× EBITDA and interest coverage of 15.3× are manageable, but the $150.71 price has tracked sideways for three months, and the 0.15% 1-year trend confirms momentum is dead.

4. EOG Resources, Inc. (EOG)

Dividend yield: 3.0% | Payout ratio: 44% | 52w drawdown: 10%

Earnings yield of 7.4% at a 10% drawdown creates the highest absolute earnings power per dollar invested on this screen, and the 44% payout ratio leaves $2.80 in retained FCF for every $1.00 distributed as dividends. Gross margin of 63.4% and ROIC of 15.2% place EOG in the top tier of U.S. shale operators, and net debt of 0.35× EBITDA gives the company firepower to accelerate buybacks or bolt-on acreage deals.

Michael T. Kerr, Jeffrey R. Leitzell, and Robert P. Daniels all filed Form 4 purchases on May 4, pushing net insider shares up 128,155 over six months at a 10.5% buy ratio versus 1.2% sell ratio. The dollar value of those adds totals $5.46 million, the highest insider commitment on the energy names this week.

Revenue declined 3.4% year-over-year, bucking the sector's 6.8% average growth, and the 1-year price trend of 0.08% confirms the stock is stuck in a range despite the operational efficiency. Mizuho bumped the target to $157 from $149, but that 16% upside hinges on crude staying above $75 and EOG proving it can grow volumes without margin compression.

5. Biogen Inc. (BIIB

Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: 6%

FCF yield of 6.9% at zero dividend payout signals Biogen is banking cash for pipeline investment or M&A, and the 76% gross margin matches Novartis for best-in-class pharma economics. ROIC of 7.0% lags the screen average but has climbed 220 basis points year-over-year as the Alzheimer's franchise scales and the biosimilar drag fades.

Insider Adam Keeney filed a Form 4 add on May 5, and net insider purchases total 84,208 shares over six months at a 5-to-1 buy-to-sell ratio. The $7.42 million in net insider buying over that window is the highest dollar commitment in the pharma cohort this week.

The Italian antitrust probe into multiple sclerosis drug competition flags regulatory risk that could cap pricing power on Tysabri and Tecfidera, which together represent $2.1 billion in annual revenue. Analyst upside of 13.4% to $219.27 assumes the MS franchise stabilizes and the Alzheimer's portfolio delivers on Phase 3 expectations, but the probe adds headline risk that could depress the multiple before it resolves.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

6. Gilead Sciences, Inc. (GILD

Dividend yield: 2.4% | Payout ratio: 48% | 52w drawdown: 14%

FCF yield of 5.7% at a 14% drawdown creates a 17.1% analyst upside wedge to $157.83, and the 79% gross margin is the highest on the screen. ROIC of 24.4% validates the HIV and oncology franchises, and interest coverage of 10.6× gives Gilead flexibility to lever the balance sheet for pipeline deals without stressing the dividend.

⬡ Phase 3 liver-disease data this week showed sustained normalization of the key disease marker, positioning Gilead's seladelpar as a best-in-class NASH candidate that competes against Madrigal's resmetirom and Intercept's obeticholic acid. The liver franchise contributes $1.8 billion in annual revenue, and a successful NASH approval would add $3–5 billion in peak sales to the 2028–2030 revenue base.

Harish Manwani, Kelly A. Kramer, and Jeffrey Bluestone each filed Form 4 adds on May 4, pushing net insider shares up 273,785 over six months at a 5.3% buy ratio versus 3.2% sell ratio. The $6.09 million in net insider buying is the second-highest dollar commitment on the screen after Exxon.

7. GSK plc (GSK

Dividend yield: 3.5% | Payout ratio: 63% | 52w drawdown: 16%

Earnings yield of 7.4% ties EOG for the highest absolute earnings power on the screen, and the 72% gross margin supports the 3.5% dividend through patent cliffs. ROIC of 19.9% and net debt of 1.37× EBITDA are both better than the pharma peer average, and the 16% drawdown sits in the strong-entry zone.

The expanded Arexvy label for RSV prevention in adults 50–59 at increased risk adds 18 million eligible patients in the U.S. alone, broadening the addressable market by 40% and positioning GSK to compete against Pfizer's Abrysvo in the younger cohort. Arexvy contributed $1.9 billion in 2025 revenue, and the label expansion supports a $2.5–3.0 billion run rate by 2027.

Five-year dividend growth of negative 15.6% flags that GSK cut the payout in 2022 when it spun out Haleon, and the 63% payout ratio leaves limited room for distribution growth without margin expansion. The $51.58 price sits 16% below the 52-week high despite the Arexvy momentum, and the 11.8% analyst upside to $57.66 signals the Street wants proof that the vaccines franchise can offset the Advair patent cliff before re-rating the equity.

8. Exxon Mobil Corporation (XOM)

Dividend yield: 2.8% | Payout ratio: 59% | 52w drawdown: 15%

Earnings yield of 4.0% at a 15% drawdown creates a 12.2% analyst upside wedge to $168.32, and the 2.8% dividend is covered 1.7× by free cash flow. Interest coverage of 69.4× is the highest on the screen, and net debt of 0.70× EBITDA gives Exxon dry powder for Guyana expansion and U.S. Permian bolt-ons.

Insiders bought 1.05 million net shares over six months at a 4.3% buy ratio versus 0.1% sell ratio, the highest buy-to-sell spread on the screen. The $7.11 million in net insider buying is the largest dollar commitment this week and signals management confidence at the current valuation despite the 15% drawdown.

Revenue declined 4.5% year-over-year, the worst on the energy cohort, and the 1-year price trend of 0.20% confirms the stock has gone nowhere while WTI crude rallied 18%. Market chatter around Venezuela safeguards and the Exxon-ConocoPhillips coordination adds headline risk, and the 25.3× P/E is 87% above the energy sector average, pricing in execution on the Guyana ramp and Permian synergies before either materializes.

What to Watch

• Gilead Phase 3 liver data follow-up (June): The sustained normalization of the key NASH marker positions seladelpar for a potential FDA filing in H2 2026; watch for investigator commentary at EASL in June for clues on competitive positioning against Madrigal.

• Novartis ERA kidney data (ongoing): The renal franchise competes head-to-head with AstraZeneca's $6.2 billion Farxiga franchise; incremental data on cardiovascular outcomes will determine whether Novartis can defend its $3.2 billion renal base or cede share.

• ConocoPhillips Venezuela safeguards (June–July): Market chatter suggests Exxon and ConocoPhillips are coordinating on return timelines; any concrete announcement on asset protection or production restart targets will move both stocks.

• Newmont earnings (July 23): Consensus expects $2.19 EPS on $6.6 billion revenue; the Street wants proof that the 21.3% revenue growth translates into margin expansion and that the 29.9% ROIC is sustainable at current gold prices.

Go Deeper

The dividend screener hunts for FCF-backed yields, low payout ratios, and drawdowns that create margin-of-safety entry points.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.